Direkt zum Inhalt
Merck
  • Comparison of clinical effects of prilocaine, dexamethasone added to prilocaine and levobupivacaine on brachial plexus block.

Comparison of clinical effects of prilocaine, dexamethasone added to prilocaine and levobupivacaine on brachial plexus block.

JPMA. The Journal of the Pakistan Medical Association (2014-05-29)
Aykut Saritas, Cemil Sabuncu
ZUSAMMENFASSUNG

To determine whether the addition of 8 mg dexamethasone to axillary brachial plexus block would prolong the duration of sensory and motor block in patients undergoing hand and forearm surgery. The prospective, randomised, double-blinded study was conducted at the Eskisehir Osmangazi University Medical School, Turkey, from October 2008 to December 2009. It comprised 45 American Society of Anaesthesiologists grade I and II patients under elective surgery of the hand and forearm. The patients were randomly divided into 3 groups: 5 mg/kg of 2% prilocaine was applied to Group 1; 5 mg/kg of 2% prilocaine +8mg of dexamethasone (2 ml) was applied to Group 2; and 1.5 mg/kg 0.5% levobupivacaine was applied to Group 3. Sensory and motor block onset time as well as the duration of motor and sensory block of those were monitored and recorded. SPSS 15 was used for statistical analysis. Of the 45 patients, 27 (60%) were men and 18 (40%) were women. There was no significant difference among the groups in terms of demographic data. Based on the duration of motor and sensory block, similar periods of time in Group 1 and Group 2 were noted, whereas this period was statistically different and significantly longer in Group 3 (p < or = 0.001). There were no complications encountered. The addition of dexamethasone to prilocaine prolonged the duration of sensory and motor block. It could be used as an effective adjuvant agent. Levobupivacain could be a more appropriate local anaesthetic in postoperative analgesia and prolonged surgical procedures.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Dexamethason, powder, BioReagent, suitable for cell culture, ≥97%
Sigma-Aldrich
Dexamethason – wasserlöslich, suitable for cell culture, BioReagent
Sigma-Aldrich
Dexamethason, ≥98% (HPLC), powder
Sigma-Aldrich
Dexamethason, powder, γ-irradiated, BioXtra, suitable for cell culture, ≥80% (HPLC)
Supelco
Dexamethasone solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
Dexamethason, meets USP testing specifications
Supelco
Dexamethason, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Prilocain -hydrochlorid, ≥98% (TLC)
Sigma-Aldrich
Dexamethason, tested according to Ph. Eur.
Supelco
Dexamethason, VETRANAL®, analytical standard
Dexamethason, European Pharmacopoeia (EP) Reference Standard
Bupivacain -hydrochlorid, European Pharmacopoeia (EP) Reference Standard
Dexamethason für die Systemeignung, European Pharmacopoeia (EP) Reference Standard
Dexamethason für die Peakidentifizierung, European Pharmacopoeia (EP) Reference Standard
Prilocain -hydrochlorid, European Pharmacopoeia (EP) Reference Standard